PORT-6
Phase 1- Indications
- Solid tumors
Company intelligence / Profile preview
Tarus Therapeutics
New York*, New York, USAtarustx.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Phase 1
01
Overview
Tarus developed highly potent and selective small molecule antagonists for the adenosine pathway, aiming to overcome immune suppression in solid tumors. Its lead programs targeted both single and dual blockade of A2A/A2B receptors. The most advanced program had reached Phase 1 prior to acquisition; subsequent development has continued under Portage Biotech/Cyncado Therapeutics with a focus on dual administration strategies for improved anti-tumor immunity
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (specifically adenosine receptor antagonists targeting A2A and A2B receptors)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Tarus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tarus Therapeutics.